Celtiss Therapeutics Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 11-12-2024
- Paid Up Capital ₹ 5.00 M
as on 11-12-2024
- Company Age 6 Year, 10 Months
- Last Filing with ROC 31 Mar 2019
- Revenue %
(FY 2019)
- Profit -69037.52%
(FY 2019)
- Ebitda -97012.73%
(FY 2019)
- Net Worth -31016.86%
(FY 2019)
- Total Assets 24298.88%
(FY 2019)
About Celtiss Therapeutics
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2019. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M, as per Ministry of Corporate Affairs (MCA) records.
Sayam Sekhar and Shailaja Sekhar serve as directors at the Company.
- CIN/LLPIN
U74999TG2018PTC123064
- Company No.
123064
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Mar 2018
- Date of AGM
29 Sep 2019
- Date of Balance Sheet
31 Mar 2019
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Celtiss Therapeutics Private Limited offer?
Celtiss Therapeutics Private Limited offers a wide range of products and services, including Common Disease Medicines, Skin Lightening Drugs.
Who are the key members and board of directors at Celtiss Therapeutics?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sayam Sekhar  | Director | 16-Mar-2018 | Current |
| Shailaja Sekhar | Director | 16-Mar-2018 | Current |
Financial Performance of Celtiss Therapeutics.
Celtiss Therapeutics Private Limited, for the financial year ended 2019, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 69037.52% decrease in profit. The company's net worth observed a substantial decline by a decrease of 31016.86%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Celtiss Therapeutics?
In 2019, Celtiss Therapeutics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Celtiss Therapeutics?
Celtiss Therapeutics has a workforce of 10 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Celtiss Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Celtiss Therapeutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
